Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences

References

• Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther. 2013 Dec;26(6):710–715.
   PubMed Web of Science ®Google Scholar
• Ntontsi P, Samitas K, Zervas E, et al. Severe asthma: what is new in the new millennium. Curr Opin Allergy Clin Immunol. 2020 Apr;20(2):202–207.
   PubMed Web of Science ®Google Scholar
• Zervas E, Samitas K, Papaioannou AI, et al. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 2018 Jan;4(1):00125–2017.
   PubMedGoogle Scholar
• Godar M, Blanchetot C, de Haard H, et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018 Jan;10(1):34–45.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Diamant Z, Bakakos P, et al. Towards precision medicine in severe asthma: treatment algorithms based on treatable traits. Respir Med. 2018 Sep;142:15–22.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Moore WC, Wechsler ME. Difficult-to-control asthma management in adults. J Allergy Clin Immunol Pract. 2022;10(2): 378–384.
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Usmani OS, et al. Biologics in severe asthma: the overlap endotype - opportunities and challenges. Expert Opin Biol Ther. 2020 Dec;20(12):1427–1434.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Fouka E, Papakosta D, et al. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin Exp Allergy. 2021 Feb;51(2):221–227.
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001 Aug;18(2):254–256.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190.
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):154–159.
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002;20(1):73–78.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–717.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–171.
   PubMed Web of Science ®Google Scholar
• Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Busse W, Spector S, Rosén K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–486.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Liu MC OHG, Pavord ID, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019;41(10):2041–2056.
   PubMed Web of Science ®Google Scholar
• Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145(6):1713–1715.
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8(9):1375.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Ford LB, et al. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019;123(2):222–224.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108.
   PubMedGoogle Scholar
• Licona-Limon P, Kim LK, Palm NW, et al. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14(6):536–542.
   PubMed Web of Science ®Google Scholar
• Liu S, Verma M, Michalec L, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. J Allergy Clin Immunol. 2018;141(1):257–268.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Exp Opin Ther Targets. 2020;24(8):777–792.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. New Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar
• Corren J, Chen S, Callan L, et al. The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. Ann Allergy, Asthma Immunol. 2020;125(2):211–214
   PubMed Web of Science ®Google Scholar
• Suruki RY, Daugherty JB, Boudiaf N, et al. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. New Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Siergiejko Z, Swiebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. New Engl J Med. 2017;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Bakakos A, Rovina N, Bakakos P. Treatment challenges in severe eosinophilic asthma: differential response to anti-IL-5 and Anti-IL-5R therapy. Int J Mol Sci. 2021;22(8):3969.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. New Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21(1):264.
   PubMed Web of Science ®Google Scholar
• Gow AM, Brightling CE, Kuna P, et al. Oral corticosteroid-sparing effect of tezepelumab in adults with severe asthma. In: D7. D007 Advances In Asthma Therapies. A1197–A1197. DOI:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1197.
   Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–678.
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–708.
   PubMed Web of Science ®Google Scholar
• Busse WW, Humbert M, Haselkorn T, et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020;124(2):190–196.
   PubMed Web of Science ®Google Scholar
• Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Prac. 2019;7(7):2447–2449.
   PubMed Web of Science ®Google Scholar
• Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22(11):2201–2208.
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002;20(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111(2):278–284.
   PubMed Web of Science ®Google Scholar
• Bardelas J, Figliomeni M, Kianifard F. Meng X.A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49(2):144–152.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, Chanez P, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019;122(1):41–49.
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788–797.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab versus placebo as add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28–35.
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Levy-Abitbol R, Olveira C, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years of treatment. J Allergy Clin Immunol. 2021;148(1):266–271.
   PubMed Web of Science ®Google Scholar
• Eger K, Pet L, Weersink EJM, et al. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021;9(7):2913–2915.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Forero DF, Tran S, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020;56(4):2000117.
   PubMed Web of Science ®Google Scholar
• Drick N, Milger K, Seeliger B, et al. Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma. J Asthma Allergy. 2020;13:605–614.
   PubMed Web of Science ®Google Scholar
• Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177–1185.e4.
   PubMedGoogle Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Mplizou M, Porpodis K, et al. Long-term efficacy and safety of omalizumab in patients with allergic asthma: a real-life study. Allergy Asthma Proc. 2021;42(3):235–242.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Cavaliere C, et al. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725–739.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention, 2022. [cited 2022 Jun 6]. Available from: www.ginasthma.org
   Google Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46.
   PubMed Web of Science ®Google Scholar
• Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529–1532.
   PubMed Web of Science ®Google Scholar
• Kallieri M, Zervas E, Fouka E, et al. RELIght: a two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response. Allergy. 2022; published online ahead of print 2022 May 20. 10.1111/all.15382
   PubMedGoogle Scholar
• Mukherjee M, Forero DF, Tran S, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020 Oct;56(4):2000117.
   PubMed Web of Science ®Google Scholar